WO2009030065A8 - 聚乙二醇修饰的干扰素α2a及其制备方法和应用 - Google Patents
聚乙二醇修饰的干扰素α2a及其制备方法和应用 Download PDFInfo
- Publication number
- WO2009030065A8 WO2009030065A8 PCT/CN2007/002643 CN2007002643W WO2009030065A8 WO 2009030065 A8 WO2009030065 A8 WO 2009030065A8 CN 2007002643 W CN2007002643 W CN 2007002643W WO 2009030065 A8 WO2009030065 A8 WO 2009030065A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interferon alpha
- modified
- application
- polyethylene glycol
- synthesis process
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT07800860T PT2196475E (pt) | 2007-09-04 | 2007-09-04 | Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação |
CN2007800505413A CN101636411B (zh) | 2007-09-04 | 2007-09-04 | 聚乙二醇修饰的干扰素α2a及其制备方法和应用 |
CA2698396A CA2698396C (en) | 2007-09-04 | 2007-09-04 | Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof |
PCT/CN2007/002643 WO2009030065A1 (zh) | 2007-09-04 | 2007-09-04 | 聚乙二醇修饰的干扰素α2a及其制备方法和应用 |
US12/676,511 US8597634B2 (en) | 2007-09-04 | 2007-09-04 | Interferon alpha-2a modified by polyethylene glycol and methods of preparation thereof |
KR1020107007268A KR101483814B1 (ko) | 2007-09-04 | 2007-09-04 | 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2a, 이의 합성 방법 및 용도 |
BRPI0721988-1A BRPI0721988B1 (pt) | 2007-09-04 | 2007-09-04 | Interferon alfa 2a modificado por polietileno glicol, método para preparação e uso do mesmo, e composição. |
DK07800860.4T DK2196475T3 (da) | 2007-09-04 | 2007-09-04 | Interferon alfa 2a, som er modificeret med polyethylenglycol, fremgangsmåde til syntese deraf samt anvendelse deraf |
ES07800860T ES2386575T3 (es) | 2007-09-04 | 2007-09-04 | Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación |
PL07800860T PL2196475T3 (pl) | 2007-09-04 | 2007-09-04 | Interferon alfa 2a zmodyfikowany rozgałęzioną cząsteczką glikolu polietylenowego, sposób jego syntezy i zastosowanie |
EP07800860A EP2196475B1 (en) | 2007-09-04 | 2007-09-04 | INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION |
ZA2010/01555A ZA201001555B (en) | 2007-09-04 | 2010-03-03 | Interferon alpha 2a modified by polyethylene glycol,its synthesis process and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2007/002643 WO2009030065A1 (zh) | 2007-09-04 | 2007-09-04 | 聚乙二醇修饰的干扰素α2a及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009030065A1 WO2009030065A1 (zh) | 2009-03-12 |
WO2009030065A8 true WO2009030065A8 (zh) | 2009-09-11 |
Family
ID=40428421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2007/002643 WO2009030065A1 (zh) | 2007-09-04 | 2007-09-04 | 聚乙二醇修饰的干扰素α2a及其制备方法和应用 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8597634B2 (zh) |
EP (1) | EP2196475B1 (zh) |
KR (1) | KR101483814B1 (zh) |
CN (1) | CN101636411B (zh) |
BR (1) | BRPI0721988B1 (zh) |
CA (1) | CA2698396C (zh) |
DK (1) | DK2196475T3 (zh) |
ES (1) | ES2386575T3 (zh) |
PL (1) | PL2196475T3 (zh) |
PT (1) | PT2196475E (zh) |
WO (1) | WO2009030065A1 (zh) |
ZA (1) | ZA201001555B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
MX2010002557A (es) * | 2007-09-04 | 2011-12-16 | Biosteed Gene Expression Tech Co Ltd | Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo. |
WO2009030065A1 (zh) | 2007-09-04 | 2009-03-12 | Biosteed Gene Expression Tech. Co., Ltd. | 聚乙二醇修饰的干扰素α2a及其制备方法和应用 |
BR112014005091A2 (pt) * | 2011-09-05 | 2017-06-13 | Beijing Hanmi Pharmaceutical Co Ltd | composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa |
KR20230079520A (ko) | 2014-11-06 | 2023-06-07 | 파마에센시아 코퍼레이션 | Peg화된 인터페론의 투약 요법 |
CN116120424A (zh) * | 2022-06-06 | 2023-05-16 | 江苏靶标生物医药研究所有限公司 | 一种干扰素α2b可溶性重组表达和分离纯化方法及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US6610830B1 (en) * | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
CN1243779A (zh) | 1998-07-31 | 2000-02-09 | 东莞中镇鞋材有限公司 | 纤维板及其制造方法 |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
JP4272537B2 (ja) * | 2002-03-13 | 2009-06-03 | 北京鍵▲凱▼科技有限公司 | Y型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物 |
AU2002356422A1 (en) * | 2002-11-01 | 2004-05-25 | Cadila Healthcare Limited | Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris |
EP1562634B1 (en) * | 2002-11-15 | 2006-08-23 | F. Hoffmann-La Roche Ag | Positional isomers of pegylated interferon alpha 2a |
MX2010002557A (es) | 2007-09-04 | 2011-12-16 | Biosteed Gene Expression Tech Co Ltd | Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo. |
WO2009030065A1 (zh) | 2007-09-04 | 2009-03-12 | Biosteed Gene Expression Tech. Co., Ltd. | 聚乙二醇修饰的干扰素α2a及其制备方法和应用 |
-
2007
- 2007-09-04 WO PCT/CN2007/002643 patent/WO2009030065A1/zh active Application Filing
- 2007-09-04 US US12/676,511 patent/US8597634B2/en active Active
- 2007-09-04 BR BRPI0721988-1A patent/BRPI0721988B1/pt active IP Right Grant
- 2007-09-04 KR KR1020107007268A patent/KR101483814B1/ko active IP Right Grant
- 2007-09-04 ES ES07800860T patent/ES2386575T3/es active Active
- 2007-09-04 CN CN2007800505413A patent/CN101636411B/zh active Active
- 2007-09-04 EP EP07800860A patent/EP2196475B1/en active Active
- 2007-09-04 PT PT07800860T patent/PT2196475E/pt unknown
- 2007-09-04 CA CA2698396A patent/CA2698396C/en active Active
- 2007-09-04 PL PL07800860T patent/PL2196475T3/pl unknown
- 2007-09-04 DK DK07800860.4T patent/DK2196475T3/da active
-
2010
- 2010-03-03 ZA ZA2010/01555A patent/ZA201001555B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2196475A4 (en) | 2010-10-20 |
CA2698396A1 (en) | 2009-03-12 |
EP2196475A1 (en) | 2010-06-16 |
KR20100063108A (ko) | 2010-06-10 |
US8597634B2 (en) | 2013-12-03 |
PT2196475E (pt) | 2012-09-07 |
WO2009030065A1 (zh) | 2009-03-12 |
CA2698396C (en) | 2014-01-21 |
US20100239532A1 (en) | 2010-09-23 |
DK2196475T3 (da) | 2012-09-17 |
CN101636411B (zh) | 2013-01-09 |
ZA201001555B (en) | 2010-11-24 |
PL2196475T3 (pl) | 2012-10-31 |
EP2196475B1 (en) | 2012-06-06 |
BRPI0721988B1 (pt) | 2021-07-27 |
KR101483814B1 (ko) | 2015-01-16 |
ES2386575T3 (es) | 2012-08-23 |
BRPI0721988A2 (pt) | 2016-10-18 |
CN101636411A (zh) | 2010-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007056470A3 (en) | Neuropilin antagonists | |
WO2006076594A3 (en) | Antibodies and fc fusion proteins with altered immunogenicity | |
EP3281956A3 (en) | Human antibody drug conjugates against tissue factor | |
WO2010069532A8 (en) | Antibodies against human angiopoietin 2 | |
WO2006133089A3 (en) | Improved human interferon molecules and their uses | |
IL186458A0 (en) | Skin enrichment using coq10 as the delivery system | |
IL197831A (en) | Human antibodies that bind 4cxcr, preparations containing them and their uses | |
WO2009067636A3 (en) | Modified insulin polypeptides and their uses | |
WO2007062610A3 (es) | Dendrímero con peg de cuatro ramas para la conjugación a proteínas y péptidos | |
WO2006010057A3 (en) | Therapeutic peptides | |
IL204607A0 (en) | Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof | |
PT2044076E (pt) | Processo de preparação de asenapina e de produtos intermediários utilizados no referido processo | |
WO2008121767A3 (en) | Stitched polypeptides | |
WO2008137471A3 (en) | Modified interferon beta polypeptides and their uses | |
EP3381445A3 (en) | Aqueous formulation of antibody stablised by antioxidants for parenteral administration | |
WO2008145137A3 (en) | Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering | |
SI1909843T1 (sl) | Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju | |
WO2008132229A3 (en) | Highly concentrated insulin solutions and compositions | |
WO2012064792A3 (en) | Protein complexes for antigen binding and methods of use | |
WO2008079973A3 (en) | Egfr binding peptides and uses thereof | |
IL211010A (en) | Antibody, antibody hybridoma, antibody-containing conjugate, antibody-containing drug and / or conjugate and their uses | |
MX2010002557A (es) | Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo. | |
WO2009030065A8 (zh) | 聚乙二醇修饰的干扰素α2a及其制备方法和应用 | |
JO2721B1 (en) | Derivatives of artemisia plant and its preparations and therapeutic applications | |
DE502007005902D1 (de) | -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780050541.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07800860 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010030342 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2698396 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007800860 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107007268 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12676511 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0721988 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100304 |